Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACT<br />
Janneke Meulenberg, PhD MBA,<br />
Chief Executive Officer<br />
ADDRESS<br />
De Boelelaan 1118<br />
1081 HZ Amsterdam<br />
The Netherlands<br />
Postal address:<br />
PO Box 7057<br />
1007 MB Amsterdam<br />
The Netherlands<br />
TELEPHONE<br />
+31 204 441826<br />
FAX<br />
+31 204 442126<br />
EMAIL<br />
meulenberg<br />
@orca-therapeutics.com<br />
YEAR FOUNDED<br />
2005<br />
ORCA Therapeutics BV<br />
www.orca-therapeutics.com<br />
FINANCIAL SUMMARY<br />
Current investor: Aglaia Oncology Seed Fund BV<br />
Financing Sought: 5 Million EURO<br />
COMPANY PROFILE<br />
ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the<br />
highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary<br />
technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new<br />
oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand<br />
fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of<br />
cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man.<br />
MANAGEMENT<br />
Janneke Meulenberg, PhD MBA, CEO<br />
Victor van Beusechem, PhD, CSO<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language